| Autor: |
Ashwaq Hamid Salem, Yehya, Ayappa V, Subramaniam, Muhammad, Asif, Gurjeet, Kaur, Amin M S, Abdul Majid, Chern Ein, Oon |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
World journal of gastroenterology. 28(32) |
| ISSN: |
2219-2840 |
| Popis: |
Pancreatic cancer is the most aggressive cancer type. Gemcitabine is the first line chemo-drug used for pancreatic cancer but exerts a broad spectrum of organ toxicities and adverse effects in patients.To evaluate the anti-tumour activity and toxicological effects ofMice were randomly divided into six groups of 6 mice each (No signs of toxicity or damage to vital organs were observed in all treatment groups compared to the untreated group. C5EOSEW5050ESA at 200 mg/kg and gemcitabine combination had no additive antitumor effects compared to a single treatment. Remarkably, a comparably greater response in a reduction in tumour growth, Ki-67 protein expression, and necrosis was demonstrated by 400 mg/kg of C5EOSEW5050ESA and gemcitabine combination than that of the individual agents.These results highlighted the synergistic activity of C5EOSEW5050ESA with gemcitabine to reduce pancreatic tumour growth in mice compared to a single treatment. Thus, this study provides valuable insights into using C5EOSEW5050ESA as a complementary treatment with gemcitabine for pancreatic cancer. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
